Edwards Lifesciences Corporation $EW Stock Position Lifted by Banco Bilbao Vizcaya Argentaria S.A.

Banco Bilbao Vizcaya Argentaria S.A. lifted its position in Edwards Lifesciences Corporation (NYSE:EW) by 9.2% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 218,749 shares of the medical research company’s stock after acquiring an additional 18,498 shares during the quarter. Banco Bilbao Vizcaya Argentaria S.A.’s holdings in Edwards Lifesciences were worth $17,003,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in EW. True Wealth Design LLC lifted its stake in Edwards Lifesciences by 251.5% during the third quarter. True Wealth Design LLC now owns 362 shares of the medical research company’s stock worth $28,000 after purchasing an additional 259 shares during the last quarter. Hantz Financial Services Inc. increased its stake in Edwards Lifesciences by 76.6% during the third quarter. Hantz Financial Services Inc. now owns 378 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 164 shares during the last quarter. Rakuten Securities Inc. increased its stake in Edwards Lifesciences by 413.7% during the second quarter. Rakuten Securities Inc. now owns 375 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 302 shares during the last quarter. Steigerwald Gordon & Koch Inc. acquired a new stake in shares of Edwards Lifesciences during the third quarter worth $30,000. Finally, Strengthening Families & Communities LLC bought a new position in shares of Edwards Lifesciences in the 3rd quarter worth about $34,000. 79.46% of the stock is currently owned by institutional investors.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 1,019 shares of Edwards Lifesciences stock in a transaction on Wednesday, March 11th. The stock was sold at an average price of $85.38, for a total transaction of $87,002.22. Following the sale, the vice president owned 33,934 shares of the company’s stock, valued at $2,897,284.92. The trade was a 2.92% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Scott B. Ullem sold 13,000 shares of the business’s stock in a transaction on Wednesday, March 11th. The stock was sold at an average price of $84.92, for a total value of $1,103,960.00. Following the transaction, the chief financial officer owned 39,699 shares of the company’s stock, valued at $3,371,239.08. This trade represents a 24.67% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 61,718 shares of company stock worth $5,236,281. Company insiders own 0.34% of the company’s stock.

Edwards Lifesciences Trading Down 3.3%

Shares of NYSE:EW opened at $81.82 on Monday. The company has a quick ratio of 3.09, a current ratio of 3.72 and a debt-to-equity ratio of 0.06. The company’s 50-day moving average price is $82.41 and its 200 day moving average price is $81.58. The company has a market cap of $47.52 billion, a PE ratio of 44.71, a P/E/G ratio of 2.13 and a beta of 0.93. Edwards Lifesciences Corporation has a fifty-two week low of $65.94 and a fifty-two week high of $87.89.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Tuesday, February 10th. The medical research company reported $0.58 EPS for the quarter, missing the consensus estimate of $0.62 by ($0.04). Edwards Lifesciences had a return on equity of 14.50% and a net margin of 17.69%.The firm had revenue of $1.57 billion during the quarter, compared to the consensus estimate of $1.54 billion. During the same quarter last year, the company posted $0.59 EPS. Edwards Lifesciences’s revenue for the quarter was up 13.3% on a year-over-year basis. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. Sell-side analysts anticipate that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Analysts Set New Price Targets

EW has been the subject of several research reports. Stifel Nicolaus set a $110.00 price target on shares of Edwards Lifesciences and gave the company a “buy” rating in a report on Tuesday, January 20th. Evercore reiterated an “outperform” rating and set a $94.00 price objective on shares of Edwards Lifesciences in a research note on Monday, January 5th. Canaccord Genuity Group set a $87.00 target price on shares of Edwards Lifesciences and gave the stock a “hold” rating in a report on Wednesday, December 17th. UBS Group reaffirmed a “neutral” rating and set a $94.00 target price on shares of Edwards Lifesciences in a report on Wednesday, February 4th. Finally, BTIG Research reiterated a “buy” rating and set a $103.00 price target on shares of Edwards Lifesciences in a research report on Wednesday, February 11th. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have assigned a Hold rating to the company. According to MarketBeat.com, Edwards Lifesciences has a consensus rating of “Moderate Buy” and an average price target of $96.14.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.